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Abstract. Although a number of inflammatory cytokines have 
been shown to be associated with periodontal pathogenesis, it 
is important to investigate further whether these biomarkers 
are associated with the degree of success in nonsurgical 
treatment of chronic periodontitis. The aim of the present 
study was to quantify the total levels of interleukin (IL)‑1α, 
-1β, ‑6, ‑10 and tumour necrosis factor (TNF)‑α in gingival 
crevicular fluid (GCF) of chronic periodontitis patients prior 
to and following nonsurgical periodontal therapy. In total, 
52 GCF samples from disease sites of patients with chronic 
periodontitis, prior to and following periodontal therapy, and 
ten non‑disease sites from non‑periodontitis subjects, were 
collected and cytokine concentrations were determined using a 
multiplex method. Periodontal parameters, including bleeding 
on probing, probing pocket depth and the clinical attachment 
level, in all the sites were recorded. Untreated disease sites 
exhibited higher cytokine levels in the GCF when compared 
with the non‑disease sites. Nonsurgical periodontal therapy 
resulted in a statistically significant decrease in the total levels 
of IL-1α, -1β and ‑6 in the GCF, but not in IL‑10 or TNF‑α. The 
results support the hypothesis that proinflammatory cytokines, 
including IL‑1α, IL-1β and IL‑6, are likely to be involved in 
the pathogenesis of periodontitis and are good markers to 
evaluate the success of nonsurgical therapy in disease sites of 
patients with periodontitis.
Introduction
Chronic periodontitis is a bacterial‑induced chronic inflam-
mation within the structures that support the teeth, resulting 
in progressive attachment and bone loss (1). Chronic peri-
odontitis is considered to be a multifactorial disease, where 
clinical expression is determined by several environmental 
and host‑derived risk factors, including microbial biofilm 
composition, and genetic background susceptibility or 
systemic disorders. Host behaviour, such as oral hygiene habits 
or smoking, also influence the course of the disease (2). 
The chronic inflammatory response that occurs within the 
periodontal tissue is a complex process that involves innate 
and adaptive immune cells and their secreted molecules. It is 
currently accepted that proinflammatory cytokines produced 
locally by periodontal tissue and inflammatory immune 
cells contribute to disease progression (3), indicating them 
as putative periodontal disease biomarkers. Identification of 
molecular biomarkers that anticipate the degree of success 
of nonsurgical treatment may be of great benefit in clinical 
practice. In addition, such potential factors may aid the identi-
fication of tooth sites that have not improved at re‑evaluation. 
According to the study by Kinane et al, periodontal disease 
biomarkers can be grouped into several categories, namely, 
prognostic biomarkers that identify patients or sites most likely 
to respond to a specific treatment, and therapeutic biomarkers 
that provide a quantifiable measurement of the response to 
periodontal treatment (4). To the best of our knowledge, no 
biomarker has been shown to exhibit a prognostic value at the 
disease site or at the patient level. With regard to therapeutic 
biomarkers, several studies have hypothesised that inflam-
matory cytokines, including interleukin (IL)‑1 and tumour 
necrosis factor (TNF)‑α, may be used as biomarkers to assess 
therapeutic outcomes in chronic periodontitis, based on studies 
where a reduction in inflammatory cytokines in the gingival 
crevicular fluid (GCF) was observed in response to nonsur-
gical periodontal therapy (3,4). However, these conclusions 
have not been corroborated in other studies (5‑7). Numerous 
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studies evaluating the level of proinflammatory cytokines in 
the GCF have included a diverse array of patients, including 
patients with moderate to advanced periodontitis, patients with 
aggressive periodontitis and patients with associated chronic 
and/or systemic diseases undergoing immunosuppressive 
therapy, which is known to influence immune parameters. 
The contrasting data highlights the need for further investi-
gation. Thus, the aim of the present study was to investigate 
the influence of nonsurgical periodontal therapy on the levels 
of four typical proinflammatory cytokines, including IL‑1α, 
-1β, ‑6 and TNF‑α, as well as one anti‑inflammatory cytokine, 
IL‑10, in the GCF of patients with chronic periodontitis and no 
associated chronic pathologies. Correlation analysis was then 
performed with the clinical parameters of the disease.
Materials and methods
Study population. In total, 62 sampling sites were collected 
from subjects attending the Dental Sciences Clinic at the 
Department of Instituto Superior de Ciências da Saúde‑Norte 
(Gandra, Portugal; ISCS‑N). Informed consent was obtained 
from each patient prior to enrolment in the study and 
the experimental protocols were approved by the Ethics 
Committee of ISCS‑N, according to the Declaration of 
Helsinki. The mean age of the subjects was 45.3±12.8 years, 
and all the subjects were Caucasian. In total, 81% were female 
and 19% were male. The subjects were non‑smokers, with the 
exception of two periodontal disease subjects who smoked 
≤10 cigarettes/day. Exclusion criteria included pregnancy or 
lactation, systemic diseases or intake of medication, such as 
antibiotics, anti‑inflammatory agents or immunosuppressors, 
for six months prior to the study due to their possible effects 
on the immune or inflammatory response. 
Periodontal examination. All patients received a compre-
hensive periodontal examination, which included the 
determination of the probing pocket depth (PPD), bleeding on 
probing (BOP) and clinical attachment level (CAL). PPD deter-
mination was performed by measuring the gingival pocket 
(mm) using a graduated periodontal probe (CP11; ASA Dental, 
Bozzano Massarosa, Italy) at each surface of the teeth in the 
dentition (six sites per tooth: mesiobuccal, buccal, distobuccal, 
mesiolingual, lingual and distolingual). Measurements were 
performed starting from the free edge of the gum to the deep 
groove with the probe parallel to the long axis of the tooth. 
BOP during the measuring of previous parameters was present 
or absent, and BOP positive was considered an objective sign 
of gingival inflammation. CAL, which represented the clinical 
approach of the adhesion level of the tissue to the root surface, 
was evaluated using the same graduated probe, corresponding 
to the distance (mm) between the cemento‑enamel junction 
and the deep groove. 
Periodontal treatment and re‑evaluation. Following peri-
odontal examination, patients with chronic periodontitis were 
enrolled in a nonsurgical periodontal treatment plan. Thus, the 
treatment provided to each patient consisted of scaling and root 
planning in the affected sites. Scaling comprised the removal 
of tartar infragingival and root planning on the surfaces of 
the teeth that had a PPD of ≥4 mm. Following the completion 
of treatment, follow‑up (re‑evaluation) was performed. The 
follow‑up was performed once, 2 months after treatment
Site selection and sample collection. In total, 52 samples were 
collected from disease sites (PPD, ≥4 mm) of chronic peri-
odontal disease subjects and ten samples were collected from 
non‑disease sites of subjects without periodontitis. Subjects 
received instruction to not eat, drink or brush the teeth for 1 h 
prior to GCF sampling. Prior to GCF sampling, the individual 
tooth was isolated with cotton rolls, supragingival plaque was 
carefully removed and the site was gently air‑dried with an air 
syringe. A sterile paper point (Dentsply Maillefer, Tulsa, OK, 
USA) was inserted in each selected pocket until mild resistance 
was felt, left in the crevices for 30 sec and then immediately 
transferred into sterile eppendorf tubes, which were stored at 
-20˚C until required for further analysis. In cases of visible 
contamination with blood, the paper point was discarded and a 
new site was selected. In periodontitis patients, GCF collection 
was performed at two points; the baseline prior to therapy and 
post‑therapy at the periondontal re‑evaluation.
Processing GCF samples. For GCF cytokine determination, 
paper points were thawed, cut to 1 cm in length and thawed 
with 50 µl phosphate‑buffered saline solution 1X [13 mM 
Na2HPO4, 7 mM NaHPO4, 100 mM NaCl (pH 7.0)] at 4˚C over-
night. Next, the paper points were centrifuged at 13,000 x g for 
10 min at 4˚C. Following centrifugation, 25-µl samples were 
used for cytokine evaluation with a multiplex immunoassay. 
Determination of cytokine levels. Cytokine (IL‑1α, -1β, -6, 
‑10 and TNF‑α) concentrations were determined using a 
commercial multiplex fluorescent bead‑based immunoassay 
kit (Human Cytokine/Chemokine Kit ‑ MPXHCYTO‑60K; 
Millipore Corporation, Billerica, MA, USA) in a Luminex® 
200™ analyser (Luminex Corporation, Austin, TX, USA). 
Raw data (mean fluorescence intensity) were analysed using 
ISTM 2.3 software (Luminex Corporation). Measurements 
were performed according to the manufacturer's instructions, 
and standards and samples were measured in duplicate. The 
minimum detectable concentrations for each cytokine were 
0.1 pg/ml for IL‑1α, IL‑10 and TNF‑α, and 0.4 pg/ml for IL‑1β 
and IL‑6. Samples with concentrations below the limit of 
detection were scored as 0. Briefly, for the assay, 25-µl GCF 
samples were added to 25 µl assay buffer and incubated with 
anti‑human multi‑cytokine beads at 4˚C for 18 h. Unbound 
material was removed by filtration. For revelation, 25 µl 
streptavidin‑phycoerythrin was added, and incubated for 
30 min. The reaction was stopped with 25 µl stop solution and 
plate reading occurred 15 min later. In the GCF samples, the 
total cytokine levels per site (pg/site) were determined with the 
assumption that all the cytokines present in the paper points 
were transferred to the phosphate‑buffered saline solution. 
Statistical analysis. Statistical analysis was conducted using 
SPSS 20.0 (IBM, Armonk, NY, USA) software and P<0.05 
was considered to indicate a statistically significant differ-
ence. Continuous variables with a normal distribution are 
expressed as the mean ± standard error of the mean and were 
analysed using parametric tests (T‑test for paired or inde-
pendent samples). Since the cytokine levels were not normally 
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distributed, these data are expressed as the median (minimum 
and maximum) and were analysed using non‑parametric tests 
(Mann‑Whitney U test for unrelated samples or Wilcoxon 
signed‑rank test for related samples). McNemar's or Fisher's 
exact tests were used to compare frequencies between related 
or unrelated samples, respectively. Spearman's ρ correlation 
coefficient was used to analyse the correlations between 
clinical parameters and cytokine levels.
Results
Clinical parameters in the sample disease sites. Examination 
of the clinical parameters in the samples of untreated 
disease sites in the periodontitis patients revealed a worse 
clinical state when compared with the non‑disease samples 
of patients without periodontitis (Table I). Thus, patients 
prior to treatment exhibited statistically significant increased 
PPD, CAL and BOP values (P<0.001, P<0.001 and P=0.005, 
respectively). Nonsurgical therapy resulted in a statistically 
significant decrease (P<0.001) in the PPD, from an average of 
4.9 to 3.4 mm, as well as a decrease in the CAL from 1.9 to 
0.7 mm (Table I). Following treatment, the sample sites from 
periodontitis patients revealed statistically significant higher 
PPD and CAL values when compared with the sample sites 
from non‑disease sites. Although the percentage of BOP 
sites decreased between 59.6%, prior to treatment, to 40.4% 
following treatment, this decrease did not reach statistical 
significance (P=0.064). 
Cytokine levels in the GCF. Among the five cytokines 
analysed, IL‑1α was the most prevalent cytokine found in the 
GCF and was detected in all the sites studied (Table II). By 
contrast, the majority of the other cytokine determinations 
were very low and in certain cases even below the detection 
levels, despite using a very sensitive method. Thus, consid-
ering all the GCF samples (from periodontitis patients and 
controls), the percentage of samples considered below the 
detection level were 13% for IL‑1β, 31% for IL‑6, 3% for IL‑10 
and 5% for TNF‑α (data not shown). However, for all the 
cytokines studied, statistically significant higher levels were 
observed in the untreated disease sites when compared with 
the control non‑disease sites (Table II). With the exception of 
IL‑6, the difference between the patient and control sites was 
maintained following periodontal treatment. 
Notably, following nonsurgical therapy, the total levels of 
the proinflammatory cytokines, IL‑1α, -1β and ‑6, , but not the 
Table I. Clinical sample site parameters.
 Disease sites (n=52)
 ----------------------------------------------------------------------------------  Non‑disease  
Parameter Prior to treatment Following treatment P‑value sites (n=10) P‑value P‑value
PPD (mm) 4.9±0.1 3.4±0.2 <0.001a 0.5±0.2 <0.001c <0.001d
CAL (mm) 1.9±0.2 0.7±0.1 <0.001a 0.0±0.0 <0.001c <0.001d
BOP sites (n) 31 21  1 
BOP sites (%) 59.6 40.4 0.064b 10.0 0.005e 0.082f
Statistics were calculated using athe Paired Samples T‑Test, bMcNemar Test, cIndependent Samples T‑Test (ccomparison between disease sites 
prior to treatment and non‑disease sites; dcomparison between disease sites following treatment and non‑disease sites), and Fisher´s Exact 
Test (ecomparison between disease sites prior to treatment and non‑disease sites; fcomparison between disease sites following treatment and 
non‑disease sites). P<0.05 indicates a statistically significant difference. PPD and CAL values are expressed as the mean ± SEM. BOP, bleeding 
on probing; CAL, clinical attachment level; PPD, probing pocket depth.
Table II. Cytokine levels in the GCF samples.
  Disease sites (n=52)
Cytokine ------------------------------------------------------------------------------------------  Non‑disease  
(pg/site) Prior to treatment Following treatment P‑valuea sites (n=10) P‑valueb P‑valuec
IL-1α 72.03 (2.17‑2099.89) 29.70 (0.75‑541.85) 0.001 11.55 (8.05‑46.25) <0.001 0.007
IL-1β   0.57 (0.00‑126.95)   0.09 (0.00‑35.15) 0.007 0.01 (0.00‑0.14) <0.001 0.014
IL‑6   0.13 (0.00‑2.32)   0.06 (0.00‑1.16) 0.047 0.00 (0.00‑0.28) 0.004 0.056
IL‑10   0.13 (0.00‑1.46)   0.07 (0.00‑0.68) 0.257 0.01 (0.00‑0.05) <0.001 <0.001
TNF‑α   0.06 (0.01‑0.52)   0.04 (0.00‑0.45) 0.243 0.01 (0.00‑0.13) 0.005 0.049
Statistics were calculated using arelated‑Samples Wilcoxon Signed Rank Test and independent‑Samples Mann Whitney U Test (bcomparision 
between disease sites prior to treatment and non‑disease sites; ccomparison between disease sites following treatment and non‑disease sites). 
P<0.05 indicated a statistically significant difference. Results are expressed as the median (minimum‑maximum). GCF, gingival crevicular 
fluid; IL, interleukin; TNF, tumour necrosis factor.
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anti‑inflammatory cytokine IL‑10, were significantly reduced. 
TNF‑α, despite being proinflammatory, did not exhibit a 
significant decrease (Table II). 
Cytokine levels and clinical parameters in the disease sample 
sites. In order to ascertain the possible clinical relevance of 
these observations, correlation analysis between the clinical 
parameters and total cytokine levels in the GCF sample sites 
was performed. As shown in Table III, positive correlations 
were observed between the levels of IL‑1α, -1β, ‑10 and TNF‑α 
(but not IL‑6) with PPD and CAL (Table III). However, no 
association was observed between the cytokine levels and 
BOP (data not shown). 
Discussion
Upon bacterial infection, gingival cells, including fibroblasts 
and epithelial cells, and cells of the immune system, such 
as macrophages and immature dendritic cells, present in 
the gingival/periodontal tissue,  secrete a diverse array of 
cytokines that function as strong local mediators of inflam-
mation to counteract infection. Among these, IL‑1α, -1β, -6 
and TNF‑α are major players in the periodontal inflammatory 
process. Nonsurgical scaling and root planning are widely 
used as the therapy of choice for the effective treatment of 
moderated and advanced chronic periodontitis. In the present 
study, the total levels of IL‑1α, -1β and ‑6 in the GCF of disease 
sites in chronic periodontitis patients decreased in response 
to nonsurgical therapy. By contrast, the levels of IL‑10 and 
TNF‑α did not change significantly. These results indicate 
that IL-1α, -1β and ‑6 may be involved in inflammation of the 
periodontal tissue.
The results indicating a decrease in the levels of the 
proinflammatory cytokines, IL‑1α, -1β and ‑6, but not IL‑10 
or TNF‑α, in the GCF of patients with chronic periodontitis, 
confirm the observations of previous studies. A previous study 
evaluating an extensive panel of GCF mediators, prior to and 
following initial therapy, in subjects with generalised severe 
chronic periodontitis, demonstrated that the total levels of 
numerous cytokines and chemokines, including IL‑1α, -1β 
and ‑6, decreased significantly in disease sites in response to 
therapy (8). Additional studies revealed that following therapy, 
the level of IL‑1β in the GCF was reduced (9), while the total 
level of IL‑10 remained unchanged (10). In addition, a previous 
study did not identify a statistically significant difference in 
the total amount of TNF‑α prior to and following periodontal 
treatment in chronic periodontitis subjects (11). Despite the 
apparent general consensus of a decrease in proinflammatory 
cytokines following nonsurgical therapy, certain studies have 
not produced such observations. In a study of 12 patients with 
moderate to advanced periodontitis, no statistically significant 
reduction in the total levels of IL‑1β and ‑10 following nonsur-
gical therapy was observed (12). Furthermore, previous studies 
have demonstrated that total IL‑1β levels were not decreased 
following therapy unless a subgroup of smokers were removed 
from the analysis (13,14). Finally, an additional study was 
unable to detect differences in the GCF levels of IL‑1β and ‑6 
following scaling and root planning (15). Thus, the results of 
the present study corroborate the existence of a close associa-
tion between nonsurgical therapy and a significant decrease in 
the total amount of inflammatory cytokines, including IL‑1α, 
-1β and ‑6. Whether the observed discrepancies between the 
studies are methodological, statistical or associated with the 
sample size or exclusion criteria requires further investiga-
tion. In this regard, it is important to consider that smoking 
is a putative factor that affects the levels of proinflammatory 
cytokines (13,14,16). 
Overall analysis of the sample sites revealed a posi-
tive correlation between the levels of the proinflammatory 
cytokines, IL‑1α and ‑1β, and the clinical severity, namely the 
PPD and CAL. These results strongly support the hypothesis 
that these cytokines are likely to be involved in the pathogen-
esis of periodontitis, as previously reported (12). 
In conclusion, the present study supports and extends the 
observations of previous studies by demonstrating that the 
inflammatory cytokines, IL‑1α and ‑1β, present in the GCF, 
correlate with clinical parameters, reinforcing the hypothesis 
that these cytokines are important markers in the pathogenesis 
of chronic periodontitis. The study also indicates that evalu-
ating the total levels of inflammatory cytokines in the GCF 
of periodontitis patients may be a useful laboratory test to 
monitor the response to nonsurgical treatment.
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Table III. Correlation analysis between clinical parameters (mm) and cytokine levels (pg/site) in GCF sample sites (n=62).
PPD correlation ρa P‑value CAL correlation ρa P‑value
IL-1α 0.386 0.002 IL‑1α 0.390 0.002
IL-1β 0.437 <0.001 IL‑1β 0.439 <0.001
IL‑6 0.230 0.072 IL‑6 0.238 0.062
IL‑10 0.457 <0.001 IL‑10 0.460 <0.001
TNF‑α 0.262 0.039 TNF‑α 0.275 0.030
aSpearman's ρ correlation coefficient; P<0.05 indicated a statistically significant difference. CAL, clinical attachment level; GCF, gingival 
crevicular fluid; PPD, probing pocket depth; IL, interleukin; TNF, tumour necrosis factor.
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